Výsledky vyhledávání - "W H, Birkenhäger"

Effects of Beta-Adrenergic Blockade on Diurnal Variability of Blood Pressure and Plasma Noradrenaline Levels

Autor: P. W. Leeuw, Kho Tl, R. Vandongen, A. Wester, W. H. Birkenhäger, Falke He

Publikováno v: Acta Medica Scandinavica. 202:389-392

The effect of propranolol on diurnal variability of BP and plasma noradrenaline levels was assessed in 15 patients with uncomplicated essential hypertension. While total variability and average noradrenaline level remained unaltered, the pressor rang

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccaa76e1726af326815eb28ff33939f7
https://doi.org/10.1111/j.0954-6820.1977.tb16849.x

Zobrazit plný text záznamu

Antihypertensive treatment and prevention of stroke and dementia

Autor: Jan A. Staessen, W. H. Birkenhäger, Ji-Guang Wang

Publikováno v: Seminars in Cerebrovascular Diseases and Stroke. 3:155-164

Hypertension is the most consistent and powerful predictor of stroke and is involved in nearly 70% of strokes. Placebo-controlled trials have proven that blood-pressure-lowering treatment reduces the incidence of stroke by 40% in middle-aged or older

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e3787fe5d7587b4cf7b3dd9558566b44
https://doi.org/10.1053/j.scds.2003.00.025

Zobrazit plný text záznamu

Treatment of diabetic patients with hypertension

Autor: Jan A. Staessen, W. H. Birkenhäger

Publikováno v: Current Hypertension Reports. 1:225-231

This review attempts to highlight the potential of calcium-channel blockers in the prevention of sequelae of diabetes mellitus and hypertension in patients who have both disorders. Evidence-based medicine is driven by the results of randomized, clini

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df0b99325c65f86cab7ced4f15790e1c
https://doi.org/10.1007/s11906-999-0025-6

Zobrazit plný text záznamu

Systolic Hypertension in Europe (Syst-Eur) Trial Phase 2: objectives, protocol, and initial progress

Publikováno v: Journal of Human Hypertension. 13:135-145

The Systolic Hypertension in Europe (Syst-Eur) trial proved that blood pressure (BP) lowering therapy starting with nitrendipine reduces the risk of cardiovascular complications in older (> or = 60 years) patients with isolated systolic hypertension

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0285ef6762d988f3c56c5cecd99ed9b8
https://doi.org/10.1038/sj.jhh.1000769

Zobrazit plný text záznamu

Placebo-Controlled Trials of Blood Pressure–Lowering Therapies for Primary Prevention of Dementia

Autor: Lutgarde Thijs, Augustine N. Odili, W. H. Birkenhäger, Jan A. Staessen, Tom Richart

Publikováno v: Hypertension. 57

To the Editor: Hypertension at middle age is a risk factor for vascular and neurodegenerative dementia later in life.1 Because populations are aging, the number of demented patients will grow 2-fold every 20 years, from 24.3 million people in 2000 to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8888d6ed4e6e52a6ec6411ea974055c9
https://doi.org/10.1161/hypertensionaha.110.165142

Zobrazit plný text záznamu

Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization

Publikováno v: Aging Clinical and Experimental Research. 3:287-302

The Syst-Eur Trial is a concerted action of the European Community's Medical and Health Research Programme. The trial is carried out in consultation with the World Health Organization, the International Society of Hypertension, the European Society o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::787916ef545c5a11de71ebcff0483c7e
https://doi.org/10.1007/bf03324024

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání